Enter the “director of prostate imaging” (at least at some centers)

As regular readers are well aware, there has for a while been an increase in the importance of new forms of high quality imaging studies in the diagnosis, work-up, and monitoring of men with prostate cancer (localized, locally advanced, and advanced). … READ MORE …

Can phi density accurately predict risk for clinically significant prostate cancer?

A new article in BJU International has suggested the possibility that Prostate Health Index density (i.e., a patient’s phi score divided by his prostate volume) may be able to predict the probability of a finding of clinically significant prostate cancer on biopsy. … READ MORE …

Another step toward a rational, risk-stratified PSA testing methodology

A newly published article in the Journal of Clinical Oncology has suggested that PSA testing between 40 and 59 years of age may be able to predict for risk of clinically significant prostate cancer later in life. … READ MORE …

New form of vaccine therapy — for low-risk prostate cancer

According to a media report on the MarketWatch web site, a company called OncBioMune is to initiate Phase II clinical trials of a new type of prostate cancer vaccine (ProscaVax). … READ MORE …

Statin therapy lowers mortality rates among Danish prostate cancer patients

According to a media release and a presentation given at the European Association of Urology (EAU) in Europe this week, statin therapy has a small but significant impact on overall and prostate cancer-specific mortality rates. … READ MORE …

Screening and the incidence of newly diagnosed, metastatic prostate cancer over time

Another article in this week’s issue of the New England Medical Journal is going to re-fuel the fire among those who advocate for widespread, frequent screening of men for risk of prostate cancer. … READ MORE …

Master gene reprogramming and the development of prostate cancer

According to an hypothesis just published by a group of researchers at the Dana-Farber Cancer Institute in Boston, they have identified “a new epigenetic program occurring as you transition from normal to tumor cells” in the development of prostate cancer. … READ MORE …